Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Cytokine Profile Comparisons Among Cytokine Release Syndrome (CRS), Macrophage Activation-like Syndrome (MAS-L) and Immune Effector Cell-Associated Hemophagocytic Syndrome (IEC-HS) in CAR-T Therapy

Blood (2024) 144 (Supplement 1): 7165.

https://doi.org/10.1182/blood-2024-211111

Published: 2024

Journal Articles

Frailty-Based Outcomes with Bispecific Antibodies in Older Patients with Multiple Myeloma

Nadine Abdallah, Matthew Rees, Supriya Gupta, Mohammed Elhaj, Radhika Bansal, Terri Menser, Gavin Schaeferle, Joselle Cook, Taxiarchis Kourelis, Rahma M Warsame, Wilson I. Gonsalves, Prashant Kapoor, Francis Buadi, Suzanne R Hayman, David Dingli, Morie A. Gertz, Yi Lin, Shaji Kumar

Blood (2024) 144 (Supplement 1): 4695.

https://doi.org/10.1182/blood-2024-211768

Published: 2024

Journal Articles

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Doris K. Hansen, Lauren C. Peres, Danai Dima, Alicia Richards, Leyla O. Shune, Aimaz Afrough, Shonali Midha, Binod Dhakal, Mehmet H. Kocoglu, Shebli Atrash, Chris Ferreri, Omar Castaneda, James A Davis, Evguenia Ouchveridze, Joseph P. McGuirk, Charlotte B Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Laura B. Oswald, Gurbakhash Kaur, Oren Pasvolsky, Mahmoud R. Gaballa, Megan M Herr, Peter A. Forsberg, Murali Janakiram, Myo Htut, Sireesha Asoori, Nilesh Kalariya, Hamza Hashmi, Ran Reshef, Douglas W Sborov, Omar Nadeem, Faiz Anwer, Jack Khouri, Shahzad Raza, Djordje Atanackovic, Melissa Alsina, Ciara Louise Freeman, Frederick L. Locke, Peter M. Voorhees, Larry D Anderson, Jr., Shambavi Richard, Thomas Martin, Yi Lin, Krina K. Patel, Surbhi Sidana

Blood (2024) 144 (Supplement 1): 936.

https://doi.org/10.1182/blood-2024-194390

Published: 2024

Journal Articles

Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy

Blood (2024) 144 (Supplement 1): 2372.

https://doi.org/10.1182/blood-2024-210474

Published: 2024

Journal Articles

Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee

Blood (2024) 144 (Supplement 1): 5166.

https://doi.org/10.1182/blood-2024-210518

Published: 2024

Journal Articles

Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy

Radhika Bansal, Andre Corraes, Monica Shaw, Lucy Holmes, Allison Kosobud, Kelsey L Haugen, Arushi Khurana, Paul J. Hampel, Urshila Durani, Suzanne R Hayman, Yucai Wang, Moritz Binder, Jonas Paludo, Saad S. Kenderian, N. Nora Bennani, Patrick B. Johnston, Stephen M. Ansell, Yi Lin

Blood (2024) 144 (Supplement 1): 2274.

https://doi.org/10.1182/blood-2024-203370

Published: 2024

Journal Articles

Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel

Lauren C. Peres, Alicia Richards, Surbhi Sidana, Laura B. Oswald, Danai Dima, Aimaz Afrough, Leyla O. Shune, Shonali Midha, Omar Castaneda, Christopher Ferreri, James A Davis, Oren Pasvolsky, Christen M. Dillard, Megan M Herr, Mehmet H. Kocoglu, Shebli Atrash, Brandon Blue, Evguenia Ouchveridze, Joseph P. McGuirk, Charlotte B Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Gurbakhash Kaur, Mahmoud R. Gaballa, Peter A. Forsberg, Ciara Louise Freeman, Murali Janakiram, Myo Htut, Sireesha Asoori, Nilesh Kalariya, Djordje Atanackovic, Binod Dhakal, Jack Khouri, Shahzad Raza, Ran Reshef, Melissa Alsina, Frederick L. Locke, Omar Nadeem, Faiz Anwer, Larry D Anderson, Jr., Shambavi Richard, Yi Lin, Thomas Martin, Peter M. Voorhees, Krina K. Patel, Doris K. Hansen, Douglas W Sborov

Blood (2024) 144 (Supplement 1): 3785.

https://doi.org/10.1182/blood-2024-210078

Published: 2024

Journal Articles

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Blood blood.2024025945.

https://doi.org/10.1182/blood.2024025945

Published: 2024

Includes: Supplemental data

Journal Articles

The Impact of Pre-Existing Autoimmune Disease on the Safety and Efficacy of CAR T-Cell Therapy for Non-Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 3125.

https://doi.org/10.1182/blood-2023-188155

Published: 2023

Journal Articles

Early Predictors of Severe Cytopenia Post CAR-T for Identification of Patients for Potential Stem Cell Collection

Blood (2023) 142 (Supplement 1): 6927.

https://doi.org/10.1182/blood-2023-189683

Published: 2023

Journal Articles

Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality

Kai Rejeski, Doris K. Hansen, Yucai Wang, Gloria Iacoboni, Emmanuel Bachy, Radhika Bansal, Olaf Penack, Fabian Mueller, Wolfgang Andreas Bethge, Javier L. Munoz, Razan Mohty, Veit L. Buecklein, Pere Barba, Frederick L. Locke, Yi Lin, Michael D. Jain, Marion Subklewe

Blood (2023) 142 (Supplement 1): 359.

https://doi.org/10.1182/blood-2023-180607

Published: 2023

Journal Articles

Outpatient Management of CAR-T and Teclistamab for Patients with Lymphoma and Multiple Myeloma

Blood (2023) 142 (Supplement 1): 253.

https://doi.org/10.1182/blood-2023-187186

Published: 2023

Journal Articles

Healthcare Utilization Outcomes of Outpatient CAR-T Cell Therapy with Remote Patient Monitoring Program

Blood (2023) 142 (Supplement 1): 5075.

https://doi.org/10.1182/blood-2023-187834

Published: 2023

Journal Articles

Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

Sireesha Asoori, Rakesh Popat, Joaquín Martínez-Lopez, Efstathios Kastritis, Larissa Brunaldi, Radhika Bansal, Andre De Menezes Silva Corraes, Kwee Yong, Catriona Mactier, Magdalena Corona, Adolfo Jesús Sáez Marín, Despina Fotiou, Meletios Athanasios Dimopoulos, Saurabh Chhabra, Sikander Ailawadhi, Ricardo Parrondo, Thomas Martin, Brian GM Durie, Yi Lin

Blood (2023) 142 (Supplement 1): 3347.

https://doi.org/10.1182/blood-2023-190793

Published: 2023

Journal Articles

Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Blood (2023) 142 (Supplement 1): 1032.

https://doi.org/10.1182/blood-2023-179868

Published: 2023

Journal Articles

Clinical Outcomes with Prophylactic Corticosteroid Use for Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): A Multicenter Analysis

Sowjanya Vuyyala, Andre De Menezes Silva Corraes, Megumi Bailey, Madiha Iqbal, Javier L. Munoz, Bradley Hunter, Radhika Bansal, Krish Patel, Mohamed A. Kharfan-Dabaja, Allison C. Rosenthal, Yucai Wang, Jonas Paludo, Patrick B Johnston, N. Nora Bennani, J. C. C. Villasboas, Urshila Durani, Stephen M Ansell, Yi Lin, Arushi Khurana

Blood (2023) 142 (Supplement 1): 6926.

https://doi.org/10.1182/blood-2023-188441

Published: 2023

Journal Articles

Prognostic Value of Month 1 Bone Marrow and PET MRD Status in CAR-T Therapy for Myeloma

Radhika Bansal, Sikander Ailawadhi, Jeremy T. Larsen, Morie A Gertz, Matthew A. Hathcock, David Dingli, Prashant Kapoor, Taxiarchis Kourelis, Suzanne R. Hayman, Rahma M Warsame, Moritz Binder, Ricardo D Parrondo, Rafael Fonseca, P. Leif Bergsagel, Shaji K Kumar, Yi Lin

Blood (2022) 140 (Supplement 1): 1862–1864.

https://doi.org/10.1182/blood-2022-166662

Published: 2022

Journal Articles

Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma

Blood (2022) 140 (Supplement 1): 2399–2401.

https://doi.org/10.1182/blood-2022-167187

Published: 2022

Journal Articles

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes

Arushi Khurana, Megumi Bailey, Madiha Iqbal, Radhika Bansal, Catherine J. Lee, Bradley Hunter, Matthew A. Lunning, Samantha Jaglowski, Michael D. Jain, Saurabh Dahiya, Veronika Bachanova, Umar Farooq, Sairah Ahmed, Brian T. Hill, Javier L. Munoz, Krish Patel, Olalekan O. Oluwole, Yi Lin

Blood (2022) 140 (Supplement 1): 4657–4660.

https://doi.org/10.1182/blood-2022-170486

Published: 2022

Journal Articles

Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions

Blood (2022) 140 (Supplement 1): 1328–1331.

https://doi.org/10.1182/blood-2022-157829

Published: 2022

NARROW

Cytokine Profile Comparisons Among Cytokine Release Syndrome (CRS), Macrophage Activation-like Syndrome (MAS-L) and Immune Effector Cell-Associated Hemophagocytic Syndrome (IEC-HS) in CAR-T Therapy

Frailty-Based Outcomes with Bispecific Antibodies in Older Patients with Multiple Myeloma

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy

Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee

Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy

Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

The Impact of Pre-Existing Autoimmune Disease on the Safety and Efficacy of CAR T-Cell Therapy for Non-Hodgkin Lymphoma

Early Predictors of Severe Cytopenia Post CAR-T for Identification of Patients for Potential Stem Cell Collection

Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality

Outpatient Management of CAR-T and Teclistamab for Patients with Lymphoma and Multiple Myeloma

Healthcare Utilization Outcomes of Outpatient CAR-T Cell Therapy with Remote Patient Monitoring Program

Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Clinical Outcomes with Prophylactic Corticosteroid Use for Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): A Multicenter Analysis

Prognostic Value of Month 1 Bone Marrow and PET MRD Status in CAR-T Therapy for Myeloma

Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes

Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only